Terms: = Ovarian cancer AND NBN, AT-V2, 4683, ENSG00000104320, ATV, FLJ10155, NBS, AT-V1, MGC87362, NBS1
115 results:
1. Syk-dependent homologous recombination activation promotes cancer resistance to DNA targeted therapy.
Zhou Q; Tu X; Hou X; Yu J; Zhao F; Huang J; Kloeber J; Olson A; Gao M; Luo K; Zhu S; Wu Z; Zhang Y; Sun C; Zeng X; Schoolmeester KJ; Weroha JS; Hu X; Jiang Y; Wang L; Mutter RW; Lou Z
Drug Resist Updat; 2024 May; 74():101085. PubMed ID: 38636338
[TBL] [Abstract] [Full Text] [Related]
2. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
[TBL] [Abstract] [Full Text] [Related]
3. Suppression of nbs1 Upregulates CyclinB to Induce Olaparib Sensitivity in ovarian cancer.
Zhong A; Cheng CS; Lu RQ; Guo L
Technol Cancer Res Treat; 2024; 23():15330338231212085. PubMed ID: 38192153
[No Abstract] [Full Text] [Related]
4. Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
Kahn RM; Selenica P; Boerner T; Roche KL; Xiao Y; Sia TY; Maio A; Kemel Y; Sheehan M; Salo-Mullen E; Breen KE; Zhou Q; Iasonos A; Grisham RN; O'Cearbhaill RE; Chi DS; Berger MF; Kundra R; Schultz N; Ellenson LH; Stadler ZK; Offit K; Mandelker D; Aghajanian C; Zamarin D; Sabbatini P; Weigelt B; Liu YL
Gynecol Oncol; 2024 Jan; 180():35-43. PubMed ID: 38041901
[TBL] [Abstract] [Full Text] [Related]
5.
Ramos CRN; Oliveira RJS; Rosa MN; Pereira AS; de Abreu RBV; van Helvoort Lengert A; Reis RM; Silva VAO; Palmero EI; Melendez ME
Curr Cancer Drug Targets; 2023; 23(11):900-909. PubMed ID: 37076963
[TBL] [Abstract] [Full Text] [Related]
6. Targeted next-generation sequencing of 21 candidate genes in hereditary ovarian cancer patients from the Republic of Bashkortostan.
Prokofyeva DS; Mingazheva ET; Valova YV; Sakaeva DD; Faishanova RR; Nurgalieva AK; Valiev RR; Bogdanova N; Dörk T; Khusnutdinova EK
J Ovarian Res; 2023 Apr; 16(1):66. PubMed ID: 37013556
[TBL] [Abstract] [Full Text] [Related]
7. Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception.
Bychkovsky BL; Lo MT; Yussuf A; Horton C; Hemyari P; LaDuca H; Garber JE; Scheib R; Rana HQ
Breast Cancer Res Treat; 2023 Jul; 200(1):63-72. PubMed ID: 36856935
[TBL] [Abstract] [Full Text] [Related]
8. Beyond BRCA: Patterns of risk-reducing surgery for non-BRCA, homologous recombination repair pathway gene variant carriers.
Lee SS; Karpel HC; Oh C; Smith J; Pothuri B
Gynecol Oncol; 2023 Mar; 170():234-240. PubMed ID: 36724586
[TBL] [Abstract] [Full Text] [Related]
9. OWL: an optimized and independently validated machine learning prediction model for lung cancer screening based on the UK Biobank, PLCO, and NLST populations.
Pan Z; Zhang R; Shen S; Lin Y; Zhang L; Wang X; Ye Q; Wang X; Chen J; Zhao Y; Christiani DC; Li Y; Chen F; Wei Y
EBioMedicine; 2023 Feb; 88():104443. PubMed ID: 36701900
[TBL] [Abstract] [Full Text] [Related]
10. Patient uptake of updated genetic testing following uninformative BRCA1 and BRCA2 results.
Macklin-Mantia SK; Clift KE; Maimone S; Hodge DO; Riegert-Johnson D; Hines SL
J Genet Couns; 2023 Jun; 32(3):598-606. PubMed ID: 36478495
[TBL] [Abstract] [Full Text] [Related]
11. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D
Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613
[TBL] [Abstract] [Full Text] [Related]
12. Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer.
Coelho R; Tozzi A; Disler M; Lombardo F; Fedier A; López MN; Freuler F; Jacob F; Heinzelmann-Schwarz V
Cell Death Dis; 2022 Oct; 13(10):909. PubMed ID: 36307400
[TBL] [Abstract] [Full Text] [Related]
13. Moderate-Risk Genes for Hereditary ovarian cancers Involved in the Homologous Recombination Repair Pathway.
Abe A; Imoto I; Ueki A; Nomura H; Kanao H
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233090
[TBL] [Abstract] [Full Text] [Related]
14. Pancreatic cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation.
Vietri MT; D'Elia G; Caliendo G; Albanese L; Signoriello G; Napoli C; Molinari AM
Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205366
[TBL] [Abstract] [Full Text] [Related]
15. Hereditary ovarian Carcinoma: cancer Pathogenesis Looking beyond
Samuel D; Diaz-Barbe A; Pinto A; Schlumbrecht M; George S
Cells; 2022 Feb; 11(3):. PubMed ID: 35159349
[TBL] [Abstract] [Full Text] [Related]
16. Clinical significance of gene polymorphisms for hereditary predisposition to breast and ovarian cancer (review of literature).
Vodolazhsky DI; Mayakovskaya AV; Kubyshkin AV; Aliev KA; Fomochkina II
Klin Lab Diagn; 2021 Dec; 66(12):760-767. PubMed ID: 35020290
[TBL] [Abstract] [Full Text] [Related]
17. Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score.
Westphalen CB; Fine AD; André F; Ganesan S; Heinemann V; Rouleau E; Turnbull C; Garcia Palacios L; Lopez JA; Sokol ES; Mateo J
Clin Cancer Res; 2022 Apr; 28(7):1412-1421. PubMed ID: 34740923
[TBL] [Abstract] [Full Text] [Related]
18. Rad50 promotes ovarian cancer progression through NF-κB activation.
Li Y; Wang S; Li P; Li Y; Liu Y; Fang H; Zhang X; Liu Z; Kong B
J Cell Mol Med; 2021 Dec; 25(23):10961-10972. PubMed ID: 34734468
[TBL] [Abstract] [Full Text] [Related]
19. nbs1 I171V variant underlies individual differences in chromosomal radiosensitivity within human populations.
Tomioka K; Miyamoto T; Akutsu SN; Yanagihara H; Fujita K; Royba E; Tauchi H; Yamamoto T; Koh I; Hirata E; Kudo Y; Kobayashi M; Okada S; Matsuura S
Sci Rep; 2021 Oct; 11(1):19661. PubMed ID: 34608183
[TBL] [Abstract] [Full Text] [Related]
20. Bilateral ovarian Germ Cell Tumor in a 46,XX Female with Nijmegen Breakage Syndrome and Hypergonadotropic Hypogonadism.
Krawczyk MA; Styczewska M; Birkholz-Walerzak D; Iliszko M; Lipska-Zietkiewicz BS; Kosiak W; Irga-Jaworska N; Izycka-Swieszewska E; Bien E
J Clin Res Pediatr Endocrinol; 2022 Jun; 14(2):251-257. PubMed ID: 34544220
[TBL] [Abstract] [Full Text] [Related]
[Next]